Sakis Mantalaris | Professor, Biomedical Systems Engineering Laboratory
Georgia Institute of Technology

Sakis Mantalaris, Professor, Biomedical Systems Engineering Laboratory, Georgia Institute of Technology

Athanasios (Sakis) Mantalaris is Professor in the W.H. Coulter Department of Biomedical Engineering at Georgia Tech & Emory since August 2018. Prior to his move to Atlanta, he was Professor of BioSystems Engineering in the Department of Chemical Engineering at Imperial College London. He received his PhD (2000) in Chemical Engineering from the University of Rochester.  His expertise is in modelling of biological systems and bioprocesses with a focus on mammalian cell culture systems, stem cell bioprocessing, and tissue engineering. He has published over 170 original manuscripts, co-edited one book, and holds several patents with several more pending. He has received several awards including the Junior Moulton Award for best paper by the Institute of Chemical Engineers (IChemE) in 2004. In 2012, he was elected Fellow of the American Institute for Medical & Biological Engineering and in 2013 he was awarded a European Research Council (ERC) Advanced Award. In 2015, he was awarded the Donald Medal by the Institution of Chemical Engineers (IChemE) for his contributions to biochemical engineering.


Conference Day 1 - Tuesday 31st March 2020 @ 17:20

Panel discussion (potency + assays): Predictive clinical functionality - guaranteeing the success of your cell therapy product

a.TowardsQuantitative-biology mechanistic CQAs to prevent failure of late stage developmentb. From ‘potency assays’ to ‘design spaces’ through ‘CQAs’c.When do we have enough quality and predictive data to assess product potency and effectiveness?d. From ‘black box’ to ‘how much is enough’?e. Realtime evaluation of release criteria?

Conference Day 2 - Wednesday 1st April 2020 @ 14:20

The role of metabolism in cellular therapeutics biomanufacturing: can metabolomics be used for quality assurance & control?

  • The application of metabolomics at all manufacturing stages (input, bioprocess, output) for the monitoring quality control and optimization of cellular therapies for clinical application.
  • Metabolomics can accurately and sensitively capture alterations in the cellular physiological state such as the loss of pluripotency of embryonic (ESCs) and induced pluripotent stem cells (iPSCs) prior to the detection by other techniques
  • The application of metabolomics for the selection of optimal differentiation protocols and for the design of bioactive materials that can enhance osteogenic differentiation of mesenchymal stem cells (MSCs)
  • We have shown that metabolomics can reveal differences in the immunosuppressive properties of MSCs
last published: 04/Jun/20 08:25 GMT

back to speakers